News & Events about Replimune Group Inc.
NAARDEN, Netherlands and MUNICH, Germany, May 04, 2023 (GLOBE NEWSWIRE) -- Forbion, a leading European life sciences venture capital firm, announces the appointment of Silva Deelan PhD, as Forbions first Head of Impact & ESG. Silva has over 15 years of experience in ESG integration, sustainability ...
Forbions largest fundraising to date750 million raised in the final close of the Forbion Ventures Fund VI 600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Forbion to 3 billion NAARDEN, The Netherlands and MUNICH, Germany...
Globe Newswire
2 months ago
WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and...
Globe Newswire
3 months ago
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline data from the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell ...
Globe Newswire
3 months ago
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, ...